CenterBook Partners LP Has $3.99 Million Position in Compass Pathways PLC Sponsored ADR $CMPS

CenterBook Partners LP reduced its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 9.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 578,828 shares of the company’s stock after selling 57,327 shares during the quarter. CenterBook Partners LP owned about 0.60% of Compass Pathways worth $3,994,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Propel Bio Management LLC grew its position in shares of Compass Pathways by 69.0% in the fourth quarter. Propel Bio Management LLC now owns 861,778 shares of the company’s stock valued at $5,946,000 after purchasing an additional 351,778 shares during the last quarter. BIT Capital GmbH grew its position in shares of Compass Pathways by 2,963.4% in the fourth quarter. BIT Capital GmbH now owns 288,814 shares of the company’s stock valued at $1,993,000 after purchasing an additional 279,386 shares during the last quarter. Intellectus Partners LLC grew its position in shares of Compass Pathways by 22.0% in the fourth quarter. Intellectus Partners LLC now owns 61,000 shares of the company’s stock valued at $421,000 after purchasing an additional 11,000 shares during the last quarter. Jefferies Financial Group Inc. grew its position in shares of Compass Pathways by 14.5% in the fourth quarter. Jefferies Financial Group Inc. now owns 1,576,905 shares of the company’s stock valued at $10,881,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Eagle Health Investments LP grew its position in shares of Compass Pathways by 62.4% in the fourth quarter. Eagle Health Investments LP now owns 1,519,388 shares of the company’s stock valued at $10,484,000 after purchasing an additional 583,938 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research report on Monday, April 20th. Morgan Stanley lifted their target price on Compass Pathways from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Canaccord Genuity Group decreased their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, March 26th. Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Finally, HC Wainwright reissued a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compass Pathways has a consensus rating of “Moderate Buy” and an average target price of $21.36.

Compass Pathways Stock Down 3.1%

CMPS stock opened at $11.73 on Tuesday. Compass Pathways PLC Sponsored ADR has a twelve month low of $2.25 and a twelve month high of $14.76. The company has a market cap of $1.58 billion, a PE ratio of -3.72 and a beta of 2.50. The business’s 50-day simple moving average is $9.11 and its 200 day simple moving average is $7.45. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. On average, research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current year.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.